Wnt signaling through the low-density lipoprotein-related receptor 5 (Lrp5) coreceptor regulates osteoblast maturation, matrix mineralization, and intermediary metabolism. In the mature osteoblast, signals downstream of Lrp5 are required for normal long-chain fatty acid b-oxidation. Mice rendered deficient for this coreceptor in osteoblasts and osteocytes accumulate body fat with elevated serum lipid levels but retain normal insulin sensitivity. In the present study, we challenged Lrp5-mutant mice with a high-fat diet (HFD) to determine whether they were more susceptible to diet-induced disturbances in glucose homeostasis. The HFD-fed Lrp5 mutant mice maintained a low bone mass phenotype with an increase in adipose tissue mass and hypertriglyceridemia and hypercholesterolemia. Examination of glucose metabolism revealed that Lrp5 deficiency in the osteoblast also resulted in hyperglycemia and hyperinsulinemia, with reductions in glucose tolerance, insulin sensitivity, and serum undercarboxylated osteocalcin. The results from in vivo genetic epistasis and in vitro studies suggest that this phenotype proceeds via the accumulation of diacylglycerol species and impaired insulin signaling in Lrp5-deficient osteoblasts. In turn, glucose uptake and osteocalcin production are diminished in mutant osteoblasts. Taken together, these data identify a link between Wnt-Lrp5 signaling and insulin signaling in the osteoblast that has the potential to influence energy balance and compound the detrimental effects of a HFD on wholebody metabolism. (Endocrinology 158: 3805-3816, 2017) L ow-density lipoprotein (LDL)-related receptor 5 (Lrp5) and the closely related Lrp6 function as coreceptors in the perception and propagation of Wntgenerated signals. Wnt ligands bind to Lrp5/6 and a seven-transmembrane frizzled receptor to form a ternary complex that signals for the cellular accumulation of the transcription factor b-catenin. The subsequent nuclear translocation of b-catenin and its interaction with other nuclear Wnt effectors then instructs a myriad of cellular responses that include, but are not limited to, proliferation and fate specification (1, 2).
L ow-density lipoprotein (LDL)-related receptor 5 (Lrp5) and the closely related Lrp6 function as coreceptors in the perception and propagation of Wntgenerated signals. Wnt ligands bind to Lrp5/6 and a seven-transmembrane frizzled receptor to form a ternary complex that signals for the cellular accumulation of the transcription factor b-catenin. The subsequent nuclear translocation of b-catenin and its interaction with other nuclear Wnt effectors then instructs a myriad of cellular responses that include, but are not limited to, proliferation and fate specification (1, 2) .
An increasing body of experimental evidence has indicated that the regulation of cellular and whole-body metabolism is a major function of Lrp5-mediated Wnt signaling. The gene encoding human LRP5 was initially identified as a candidate gene in the IDDM4 locus on chromosome 11q13, which exhibited genetic linkage to insulin-dependent diabetes mellitus (3, 4) . More recent studies have linked polymorphisms in LRP5 to increased total and LDL cholesterol levels, hypertension, an increased body mass index, and obesity (5) (6) (7) (8) (9) . Animal models exhibit similar phenotypes, as shown by Lrp5 null mice, which exhibit a reduction in glucose tolerance owing to defects in insulin secretion and develop hypercholesterolemia when fed a high-fat diet (HFD) or bred onto an ApoE 2/2 background (10, 11). Additionally, polymorphisms and loss of function mutations in other Wnt signaling components that act downstream of Lrp5 or modify its function, such as the Wnt effector T-cell factor-4 and Wnt signaling antagonist DKK1, have also been linked to alterations in metabolism in both humans and animal models (12) (13) (14) .
The effects of Wnt-Lrp5 signaling on whole-body metabolism can be partially mediated by actions in the skeleton. The osteoblast, responsible for bone formation, has recently been identified as a source of at least two metabolic hormones. The first, osteocalcin (15) , functions in a bone-pancreas endocrine loop, in which insulin stimulates osteocalcin production and bioavailability, which, in turn, acts on the pancreatic b-cells to increase insulin production and on peripheral tissues to increase insulin sensitivity (16) (17) (18) . The second, lipocalin (19) , acts in the hypothalamus to regulate feeding behavior. Additionally, because of its biomass and the energetic cost of bone remodeling (20) , bone is a site of substantial nutrient uptake (21, 22) .
Lrp5 expression by the osteoblast is required for maintenance of normal bone mass and strength (23, 24) and promotes osteoblastic differentiation and, in turn, bone formation (25) (26) (27) (28) (29) . To fuel the osteoanabolic response associated with elevated Wnt-Lrp5 signaling, the pathway impinges on the intermediary metabolism of the osteoblast. Esen et al. (30) demonstrated that Wnt3a stimulates glucose consumption by preosteoblasts cultured in vitro and that Lrp5 was required for an increase in Warburg-like metabolism. Consistent with this idea, young Lrp5 2/2 mice and those in which Lrp5 expression was disrupted in preosteoblasts exhibited reductions in serum lactate and the expression of hexokinase-2 and lactate dehydrogenase in bone (30) . In our previous studies (31), mice lacking Lrp5 in mature osteoblasts and osteocytes exhibited increases in body fat and serum lipids but retained normal glucose homeostasis. This effect appears to be secondary to impairments in fatty acid catabolism and reduced expression of enzymes involved in long-chain fatty acid b-oxidation by mature osteoblasts when Wnt-initiated signaling downstream of Lrp5, but not the closely related Lrp6 coreceptor, is impaired (31) .
In the present study, we challenged mice lacking Lrp5 in osteoblasts with a HFD to further examine the paradoxical maintenance of normal glucose and insulin levels in the face of increased adiposity and dyslipidemia. We found that Lrp5 mutant mice are sensitized to HFD feeding and develop marked impairments in glucose tolerance and insulin sensitivity in association with ectopic lipid deposition and reductions in serum uncarboxylated osteocalcin. Mechanistically, the development of these metabolic abnormalities appears to be initiated by impairments in osteoblastic insulin sensitivity that result in reduced glucose uptake and deficient osteocalcin production. Our data suggest a model in which Wnt-Lrp5 signaling, through the regulation of fatty acid catabolism, maintains insulin signaling in the osteoblast in the setting of HFD feeding and thereby affects whole-body metabolism.
Methods

Animal models
The institutional animal care and use committee of Johns Hopkins University approved all procedures involving mice. Lrp5 was disrupted in the osteoblast by crossing Lrp5 flox/flox mice, in which the second exon is flanked by loxP sites, with osteocalcin-Cre (Oc-Cre) transgenic mice (32), as previously described (25, 31) . Mice lacking the insulin receptor (IR) in osteoblasts have also been previously described (18) . Polymerase chain reaction (PCR) analysis of tail biopsy specimens was used to confirm the genotypes. The mice were housed on ventilated racks with a 14-hour light/10-hour dark cycle and fed ad libitum with a control diet (10% kcal from fat; D12450J; Research Diets) or HFD (60% kcal from fat; D12492; Research Diets) for 8 to 12 weeks.
Metabolic studies and bioassays
A OneTouch Ultra (Lifescan, Inc.) hand-held glucometer was used to assess the blood glucose levels. For glucose tolerance testing, glucose (1 g/kg body weight) was injected intraperitoneally after the mice were fasted for 6 hours. For insulin tolerance testing, the mice were fasted for 4 hours and then injected intraperitoneally with insulin (0.5 U/kg body weight). Plasma triglycerides (Sigma-Aldrich), b-hydroxybutyrate (Sigma-Aldrich), cholesterol (BioAssay Systems), free fatty acids (Sigma-Aldrich), and glycerol (Sigma-Aldrich) were measured colorimetrically in plasma collected from randomfed mice 3 hours after the initiation of the light cycle. Plasma insulin (ALPCO) and osteocalcin (Takara) were assessed by enzyme-linked immunosorbent assay. Insulin signaling in white adipose tissue (WAT) and liver was assessed by injection of insulin (0.5 U/kg) into the portal vein before excising the tissue and snap freezing for immunoblot analysis (33, 34) . The pancreata were fixed and stained with hematoxylin and eosin or with an antiinsulin antibody [Dako, A056401; research resource identifier (RRID): AB_2617169], and islet morphometry was assessed, as previously described (35) . Sections of gonadal WAT and liver were stained with hematoxylin and eosin. Tissue lipids were extracted via a modified version of the Folch method (36).
Culture of primary osteoblasts
Primary mouse osteoblasts were isolated from the calvaria of 1-to 3-day-old Lrp5 flox/flox neonates by serial digestion in 1.8 mg of collagenase/mL. For in vitro deletion of Lrp5, osteoblast cultures were infected with adenovirus encoding Cre recombinase or green fluorescent protein (Vector Biolabs). A multiplicity of infection of 100 was used in all experiments, and gene deletion was confirmed by quantitative PCR. Osteoblast differentiation was induced by supplementing a-minimal essential medium, containing 10% serum, with 10 mM b-glycerol phosphate and 50 mg of ascorbic acid/mL. Stearate (SigmaAldrich), for usage in cell culture, was resuspended in ethanol and heated at 65°C to fully dissolve. Stearate was then conjugated to bovine serum albumin by a 1:20 dilution in a 10% bovine serum albumin phosphate-buffered saline solution and heated at 65°C for 15 minutes. Cellular diacylglycerol species were determined by mass spectroscopy by the Medical University of South Carolina Lipidomics Analytical Unit. Insulinstimulated glucose uptake by osteoblasts was assessed using 2deoxyD(
Gene expression studies
Total RNA was extracted from tissues or osteoblasts grown in vitro using the TRIzol method (Life Technologies). One microgram of pure RNA was reverse transcribed using the iScript cDNA synthesis system (Bio-Rad). Two microliters of cDNA was then subjected to PCR amplification using iQ SYBR Green Supermix (Bio-Rad). Primer sequences were obtained from PrimerBank (available at: http://pga.mgh.harvard.edu/ primerbank/index.html). The reactions were normalized to endogenous 18S reference transcript. Cellular protein was collected in Triton X-100 lysis buffer and prepared for immunoblotting according to standard technique. Antibodies specific for Akt (9272; RRID: AB_329827), phosphorylatedAkt (Ser473, 9271; RRID: AB_329825), Jnk (9252; RRID: AB_2250373), phosphorylated-Jnk (4668; RRID: AB_823588), Irs-1 (3194; RRID: AB_561124), IR (3025; RRID: AB_2280448), and b-actin (3700; RRID: AB_2242334) were obtained from Cell Signaling Technologies.
Skeletal phenotyping
High-resolution images of the mouse femur were acquired using a desktop microtomographic imaging system (Skyscan 1172; Bruker) in accordance with the recommendations of the American Society for Bone and Mineral Research (38) . Bones were scanned at 50 keV and 200 mA using a 0.5-mm aluminum filter with an isotropic voxel size of 10 mm. Trabecular bone parameters were assessed in a volume of interest 500 mm proximal to the growth plate and extending for 2 mm (200 computed tomography slices). Marrow adipocytes were quantified in hematoxylin and eosin-stained sections of the distal femur after decalcification in 10% EDTA.
Statistical analysis
All results are expressed as the mean 6 standard error of the mean. Statistical analyses were performed using unpaired, twotailed Student t or analysis of variance tests, followed by post hoc tests. P , 0.05 was considered statistically significant. In all figures, *P # 0.05.
Results
HFD-fed Lrp5 mutant mice exhibited an increase in fat mass and hepatic lipid deposition
Genetic ablation of the Wnt coreceptor Lrp5 in mature osteoblasts and osteocytes (Lrp5 flox/flox ;Oc-Cre TG/+ , hereafter referred to as DLrp5) resulted in a low bone volume phenotype reminiscent of the human condition osteoporosis pseudoglioma, as well as the accumulation of adipose tissue with elevated serum triglycerides and free fatty acids (25, 31) . We speculated that these phenotypes would render DLrp5 mice more sensitive to dietinduced disturbances in the metabolism and that the mutant mice would develop derangements in glucose homeostasis that were not evident with a standard chow diet. To test this hypothesis, cohorts of 8-week-old male control (Lrp5 flox/flox ) and DLrp5 mice were fed a HFD (60% of kcal from fat) or an isocaloric control diet (10% of kcal from fat) ad libitum for 12 weeks. Consistent with our previous findings (31), DLrp5 mice fed a control diet exhibited a decrease in body weight (Fig. 1A) . However, this deficit rapidly resolved with HFD feeding, as the body weights of the control and DLrp5 mice were identical within 2 weeks (Fig. 1B) . The body weights remained equivalent for the duration of the study; however, a comparison of the total weight gain by the HFD-fed mice relative to those fed a control diet revealed a threefold greater increase in the DLrp5 mice (Fig. 1C) . At necropsy, the HFD-fed Lrp5 mutant mice were noticeably fatter than their control littermates (Fig. 1D) , and the weights of the gonadal fat pad and retroperitoneal fat pad were increased significantly (Fig. 1E) . Histological examination of WAT depots suggested the increase in adipose tissue mass in DLrp5 mice was the result of a more dramatic hypertrophic response because adipocyte size was significantly increased in gonadal WAT of DLrp5 mice relative to that of the controls ( Fig.  1G and 1H) . A modest increase in adipocyte size was also evident in the inguinal WAT of DLrp5 mice (Fig. 1G) , middle panel], although the mass of this depot was comparable in the control and mutant mice. The interscapular brown adipose tissue mass and the weights of other major organs, including the liver, were also normal in the DLrp5 mice compared with those of the controls (Fig. 1F) . However, lipid deposition was more prominent in the histological sections of the liver taken from DLrp5 mice relative to that of the controls (Fig. 1G) , which was confirmed by extracting and quantifying liver triglycerides (Fig. 1I) . Corresponding changes in lipid homeostasis were also evident in the serum of DLrp5 mice, which exhibited increases in triglycerides and cholesterol compared with those of the controls ( Table 1) .
The prevalence of marrow adipocytes in the distal femur was comparable in the control and DLrp5 mice fed a HFD ( Fig. 1J and 1K ), indicating that the effects of Lrp5 deficiency in osteoblasts on WAT accumulation did not extend to lineage allocation of marrow progenitor cells. Additionally, the development of a more severe metabolic phenotype in HFD-fed DLrp5 mice was not accompanied by greater reductions in the trabecular bone volume. The control mice fed a HFD exhibited a 12% decrease in trabecular bone volume per tissue volume in the distal femur relative to those fed the control diet; however, the bone volume in the DLrp5 mice, although consistently reduced relative to their control littermates consuming each diet (44% and 32% with the control and HFD diet, respectively), was not further decreased by HFD feeding. This finding might have resulted from the engagement of compensatory mechanisms designed to maintain a minimum level of trabecular bone mass necessary for the fulfillment of the other physiologic functions of bone. Therefore, DLrp5 mice fed a HFD maintained many of the metabolic phenotypes evident in the chow-fed mice, including increase adiposity and dyslipidemia (31), but were more susceptible to HFDinduced weight gain and ectopic lipid accumulation.
Glucose metabolism is impaired in HFD-fed DLrp5 mice
Random fed and fasting blood glucose levels were normal in DLrp5 mice fed a control diet (data not shown); however, the HFD-fed mutant mice exhibited a strong trend toward hyperglycemia in the fed state (P = 0.06) and a significant increase in blood glucose levels after fasting ( Fig. 2A) and an increase in serum insulin levels (Fig. 2B) suggestive of the development of insulin resistance. To examine this more directly, control and DLrp5 mice were subjected to standard glucose tolerance and insulin tolerance tests. HFD-fed DLrp5 mice exhibited impairments in glucose handling with both procedures compared with their control littermates (Fig.  2C-2E) , which further confirmed a state of impaired glucose homeostasis in the mutant mice.
We next performed histomorphometric analyses in the pancreas and examined the response of WAT and liver to insulin to determine the basis for this phenotype. b-Cell islets in the pancreas of DLrp5 mice were significantly larger than those in control mice (Fig. 2F and 2G ), which accords with a need for greater insulin production owing to insulin resistance and suggests that the reduction in glucose tolerance did not result from impaired insulin secretion. Rather, insulin sensitivity, indexed by the phosphorylation of Akt after the administration of a bolus of insulin, was reduced in both gonadal WAT and the liver (Fig. 2H-2J) . Additionally, the expression of insulin-responsive genes was altered in each of these tissues, with WAT exhibiting a substantial reduction in the messenger RNA levels of Pparg (peroxisome proliferator-activated receptor-g), and the liver maintaining an increase in the expression of genes involved in gluconeogenesis and glycogenolysis ( Fig. 2K and 2L) .
Because the Lrp5 gene is only recombined in bone in the mutant mice (25, 31) and the metabolic phenotype of HFD-fed Lrp5 mice is similar to that of mice deficient for osteocalcin (15), we questioned whether reductions in serum osteocalcin might underlie the impairments in glucose metabolism in the mutant mice. The serum levels of carboxylated osteocalcin were not affected by loss of Lrp5 function (Fig. 2M) ; however, the levels of uncarboxylated osteocalcin, the putative hormonal form (15, 16) were reduced by 47% (Fig. 2N) . Thus, HFD feeding results in the development of impaired glucose handling and reduces adipose and liver insulin sensitivity in mice lacking Lrp5 in the osteoblast, potentially as a result of deficient hormonal osteocalcin production.
Loss of Lrp5 expression reduces insulin sensitivity in bone and stearate treated osteoblasts
The reduction in serum uncarboxylated osteocalcin levels suggested that the disturbances in glucose metabolism evident in HFD-fed DLrp5 mice might develop as a result of insulin resistance in bone (39) . To test this idea, Akt phosphorylation was assessed in the tibia of control and DLrp5 mutant mice after the administration of a bolus of insulin. DLrp5 mutant mice fed a control diet exhibited a normal response to insulin (data not shown). However, the Akt phosphorylation levels after insulin administration were consistently reduced in the HFD-fed mutant mice relative to those of the controls (Fig. 3A and  3B) . A similar response was observed in cultured osteoblasts. Although genetic ablation of Lrp5 expression alone (Fig. 3C) did not affect insulin sensitivity in vitro (Fig. 3D) , mutant osteoblasts were sensitized to the addition of the fatty acid stearate (mimicking HFD feeding) and exhibited an impaired phosphorylation response to insulin ( Fig. 3E and 3F) . Upstream of Akt phosphorylation, stearate-treated DLrp5 osteoblasts exhibited normal IR protein levels ( Fig. 3G and 3H ) but reduced levels of Irs1. This effect was accompanied by an increase in the phosphorylation of the kinase Jnk and a more substantial accumulation of C16:0/18:0, C16:0/16:0, and C18:0/18:0 diacylglycerol species (Fig. 3I) , both of which are known to stimulate insulin resistance (40) (41) (42) . Downstream of Akt, the ability of insulin to stimulate glucose uptake and enhance the expression of osteocalcin were also markedly impaired in cultures of mutant osteoblasts treated with stearate ( Fig. 3J and 3K ). These data imply that Lrp5 deficiency renders the osteoblast more sensitive to stimuli that induce insulin resistance.
Epistasis reveals a genetic interaction between Lrp5
and IR in response to HFD feeding To ensure that reduced insulin signaling in the osteoblast is an underlying cause of the development of insulin resistance in vivo in HFD-fed DLrp5 mutant mice, we performed a genetic epistasis experiment in which DLrp5 (Fig. 4A) , fat pad weight (Fig. 4B) , and glucose homeostasis (Fig. 4C-4H ) were comparable in control (Cre-) mice and those lacking either one allele of Lrp5 (Lrp5D/+) or one allele of IR (IRD/+). However, the Lrp5D/+;IRD/+ mice accumulated a greater adipose tissue mass (Fig. 4B), were hyperinsulinemic (Fig. 4D) , and . Because steady-state Akt phosphorylation levels were similar in control and DLrp5 mice, the results are presented as the percentage of increase in Akt phosphorylation. Quantitative PCR analysis of insulin-responsive genes in (K) gWAT and (L) liver of control and DLrp5 mice (n = 6 mice per genotype). Quantification of (M) carboxylated (Gla) and (N) uncarboxylated (Glu) osteocalcin in the serum of control and DLrp5 mice (n = 6 mice per genotype). Data are representative of mean 6 standard error of the mean. *P , 0.05 vs control. mRNA, messenger RNA.
exhibited impairments in glucose tolerance and insulin tolerance (Fig. 4E-4H ), indicating that Lrp5 and IR are in the same genetic pathway in vivo. Additionally, the levels of serum carboxylated and uncarboxylated osteocalcin were significantly reduced in Lrp5D/+;IRD/+ mice ( Fig. 4I  and 4J ), suggesting that the pathway regulates glucose metabolism in the context of a HFD via the production of this bone-derived hormone.
Discussion
Loss and gain of function mutations in LRP5 in humans and its murine ortholog exert profound control over bone mass and result in the generalized osteopenia of osteoporosis pseudoglioma or the high bone mass phenotype, respectively (23-25, 27, 43) . These same mutations also affect the body mass and the development of adipose tissue. Loh et al. (44) reported that in humans, high bone mass mutations are associated with a metabolically favorable body fat distribution and increased insulin sensitivity, and low bone mass, loss of function mutations are associated with increased abdominal fat accumulation. Our previous work (31) and the data from the present study suggest that the alterations in whole-body metabolism associated with LRP5 mutations can be partially explained by the function of LRP5 in the osteoblast. Genetic ablation of Lrp5 expression specifically in the mature osteoblast and osteocyte leads to the accumulation of adipose tissue and the development of dyslipidemia, even in mice fed a standard chow diet, presumably as a result of reduced fatty acid catabolism in bone (31) . That osteoblast-specific Lrp5 mutant mice maintained normal glucose homeostasis, even with an increased adipocyte size and elevated serum triglyceride and nonesterified fatty acid levels, suggests that the mice would be more sensitive to diet-induced disturbances in glucose metabolism.
Consistent with our overall hypothesis, HFD feeding led to the development of more severe disturbances in metabolism in DLrp5 mice, which appeared to proceed via alterations in the insulin signaling pathway that were not affected in the chow fed mice or by Lrp5 genetic ablation alone. Lrp5 mutant mice fed a HFD rapidly gained body weight and quickly overcame the decrease in body weight of mutants fed the control diet and observed previously in the chow diet-fed mutant mice (31) . The basis for the reduced body weight in the chow/control diet-fed mutants is not currently known, because the limb and body lengths were similar in the control and mutant mice (unpublished data). However, the accelerated weight gain relative to controls consuming a HFD accords with the reduced whole-body energy expenditure evident in DLrp5 mice (31) . Additionally, 12 weeks of HFD feeding resulted in the Lrp5 mutant mice exhibiting derangements in glucose homeostasis, which were not evident in the chow-fed mutants. This phenotype was marked by hyperglycemia and reduced glucose and insulin tolerance, which is unlikely to be the result of a defect in insulin secretion, because the mutant mice exhibited hyperinsulinemia and the b-cell islets were hypertrophied relative to controls. Instead, we expect that at least two physiologic changes secondary to Lrp5 deficiency in the osteoblast account for the impaired insulin sensitivity. First, the reduced capacity for Lrp5 osteoblasts to metabolize fatty acids leads to their redistribution and storage in adipose tissue and the liver and impairs insulin signaling in these tissues. Hepatic steatosis and adipocyte hypertrophy are both associated with reduced insulin sensitivity (45) (46) (47) (48) . Second, impaired insulin signaling in Lrp5-deficient osteoblasts reduces skeletal glucose uptake and the production of osteocalcin. Insulin stimulates glucose uptake by the osteoblast via a Glut-4-dependent mechanism, thereby allowing the skeleton to contribute to the clearance of glucose (37) . In parallel, reductions in osteoblastic insulin signaling have been shown previously to contribute to the development of HFD-induced insulin resistance via decreased osteocalcin production (39). Wei et al. (39) reported that deleting a single of allele of the IR in osteoblasts was sufficient to render mice more sensitive to a HFD, which was not the case in our study. This contrasting finding could have resulted from differences in the selection of Cre-expressing mouse lines and the resulting differences in the targeting of the osteoblast population. Nonetheless, osteocalcin increases insulin sensitivity in a number of tissues and might also contribute to the regulation of ectopic lipid deposition (17, 49, 50) .
Our data indicate that Lrp5 and the IR are in the same genetic cascade in the osteoblast only in the context of a HFD and that accumulation of fatty acid derivatives in Lrp5-mutant osteoblasts lead to the downregulation of insulin signaling in the osteoblast. These findings align with previous studies that also documented an interaction between Lrp5 and IR. Palsgaard et al. (51) demonstrated that Lrp5 is essential to normal insulin signaling in preadipocytes and that the proteins physically interact. Much like stearatetreated DLrp5 osteoblasts, preadipocytes in which Lrp5 expression was knocked down exhibited a reduction in insulin-stimulated Akt phosphorylation. We could not detect a direct interaction between Lrp5 and IR in the osteoblast (data not shown), and insulin signaling proceeded normally in Lrp5-mutant osteoblasts in the absence of exogenous fatty acids, which suggests a different mechanism of interaction in bone. Rather, the reduced capacity for fatty acid catabolism in Lrp5-mutant osteoblasts likely leads to the accumulation of diacylglycerol species and the subsequent downregulation of Irs1. This mechanism of fatty acidinduced insulin resistance in the osteoblast accords with the findings of Samuel et al. (48, 52) and Szendroedi et al. (53) in the liver and muscle. Lrp5 has also been suggested to have a direct, Wnt-independent role in glucose uptake in mammary endothelial cells (54) . However, again, this does not appear to be the case in osteoblasts, because glucose uptake was normal in Lrp5-deficient cells in the absence of stearate.
The maintenance of similar trabecular bone volume fractions in DLrp5 mutant mice fed a control diet and HFD was surprising considering that a reduction was observed in control mice fed a HFD and insulin signaling is anabolic in bone (18) . However, several explanations are possible for this observation. As indicated, it is possible that the bone volume is not further decreased in HFD-fed DLrp5 mice because a minimum bone surface is necessary for the tissue to serve as an ion reservoir and to fulfill the other physiological functions of bone. Another possibility is that the more rapid weight gains evident in HFD-fed mutants maintain bone volume by mechanical effects. Perhaps the most intriguing possibility is that HFD feeding reduces bone mass by modifying Wnt signaling, which is already reduced in mutant mice. HFD downregulates Wnt signaling in a number of tissues (55) (56) (57) , and oxidized LDL, for instance, can attenuate Wnt signaling in osteoblasts by activating Pparg, which suppresses b-catenin activity (58) . Determining the exact mechanism will require additional experiments.
In conclusion, these studies identified an interaction between Wnt-Lrp5 and insulin signaling, two osteoanabolic pathways, that influence glucose homeostasis in the context of a HFD. Our results add to the increasing body of work that implicates the skeleton and the Wnt signaling pathway, through its actions in the osteoblast, in the regulation of whole-body metabolism.
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